Rezdiffra (Resmetirom) and Testosterone Interaction

Why This Combination Comes Up Clinically

Metabolic dysfunction-associated steatohepatitis (MASH) and hypogonadism share a bidirectional relationship rooted in insulin resistance, visceral adiposity, and chronic inflammation. Resmetirom (brand name Rezdiffra) received FDA approval in March 2024 as the first drug indicated specifically for MASH with moderate to advanced fibrosis [1]. Testosterone replacement therapy (TRT) remains a mainstay treatment for male hypogonadism, a condition present in up to 45% of men with metabolic syndrome according to data from the European Male Ageing Study (EMAS, N=3,369) [2].

The overlap is not rare. Men diagnosed with MASH frequently present with low testosterone, and prescribers increasingly face the question of whether these two therapies can run in parallel. A 2020 cross-sectional analysis in the Journal of Clinical Endocrinology & Metabolism found that men with biopsy-confirmed NAFLD/NASH had total testosterone levels averaging 30% lower than matched controls without liver disease [3]. That prevalence makes this drug combination a practical clinical reality, not a theoretical edge case.

Pharmacokinetic Profile: Where the Pathways Cross

Resmetirom is metabolized primarily through CYP2C8 and, to a lesser extent, CYP3A4 according to the FDA-approved prescribing information [1]. Testosterone undergoes hepatic metabolism via CYP3A4 along with significant contribution from 5-alpha reductase and UGT2B17 glucuronidation pathways [4]. The shared CYP3A4 involvement is the node that draws attention.

In practice, this overlap is unlikely to produce clinically meaningful kinetic changes. Resmetirom's primary clearance route is CYP2C8, not CYP3A4 [1]. Testosterone at physiologic replacement doses (producing serum levels of 300 to 1 to 000 ng/dL) does not act as a strong CYP3A4 inhibitor or inducer [4]. The FDA label for resmetirom lists strong CYP2C8 inhibitors (such as gemfibrozil) as drugs requiring dose adjustment, but does not flag testosterone or androgens as interacting agents [1].

No published pharmacokinetic interaction study pairing resmetirom with testosterone exists as of May 2026. This absence itself is informative. The FDA's clinical pharmacology review for resmetirom evaluated interactions with CYP2C8, CYP3A4, OATP1B1, and OATP1B3 substrates and modulators [1]. Testosterone was not identified as a concern in any of those assessments.

Regarding P-glycoprotein (P-gp) transport, resmetirom is a substrate of P-gp [1]. Testosterone does not meaningfully inhibit P-gp at therapeutic concentrations [4]. This transporter pathway adds no additional interaction risk.

Pharmacodynamic Overlap: The Real Clinical Consideration

The meaningful interaction between these drugs is pharmacodynamic, not pharmacokinetic. Both medications independently influence three systems that require monitoring in MASH patients: lipid metabolism, hepatic function, and hematologic parameters.

Lipid effects. Resmetirom lowers LDL cholesterol. In the MAESTRO-NASH trial (N=966), resmetirom 100 mg reduced LDL-C by approximately 14% from baseline at 52 weeks compared with placebo [5]. Testosterone's effect on lipids is more complex. A meta-analysis of 29 RCTs (N=1,958) published in the Journal of Clinical Endocrinology & Metabolism found that TRT reduced total cholesterol and LDL modestly but also lowered HDL by an average of 0.49 mmol/L [6]. The net lipid effect of the combination depends on formulation, dose, and individual metabolic context. The LDL-lowering from resmetirom may partially offset testosterone's HDL-suppressive tendency, but this has not been studied directly.

Hepatic transaminases. Both drugs can raise ALT and AST, though through different mechanisms. Resmetirom's effect on transaminases is generally favorable in MASH: the MAESTRO-NASH trial showed ALT reductions of 36% at 52 weeks in the treatment arm [5]. Testosterone, by contrast, can raise hepatic transaminases, particularly with oral formulations (methyltestosterone, oral testosterone undecanoate) [4]. Injectable and transdermal testosterone carry lower hepatotoxicity risk but still warrant liver function monitoring per the Endocrine Society's 2018 guideline [7].

Dr. Kenneth Cusi, who led the AASLD's practice guidance on NAFLD/NASH management, has stated: "Any co-prescribed medication in the MASH population demands liver safety monitoring at a frequency appropriate to the agent's hepatic risk profile" [8].

Hematologic effects. Testosterone increases erythropoiesis. The Testosterone Trials (TTrials, N=788) documented hematocrit increases exceeding 50% in 3.5% of testosterone-treated men versus 0.4% on placebo [9]. Resmetirom has not been associated with polycythemia. Patients with advanced liver fibrosis, the population taking resmetirom, may have altered erythropoietin dynamics due to portal hypertension. This makes hematocrit monitoring doubly relevant when testosterone is co-prescribed.

A Monitoring Framework for the Combination

Patients taking both resmetirom and testosterone benefit from a structured monitoring schedule that accounts for the pharmacodynamic overlaps described above. The following protocol synthesizes recommendations from the Rezdiffra prescribing information [1], the Endocrine Society's testosterone therapy guideline [7], and AASLD practice guidance [8].

Baseline (before starting the second agent):

• Complete metabolic panel including ALT, AST, total bilirubin, and alkaline phosphatase
• Fasting lipid panel (LDL-C, HDL-C, triglycerides, total cholesterol)
• CBC with hematocrit
• Total and free testosterone, SHBG
• FibroScan or FIB-4 score if not performed within the prior 6 months

Week 4 to 6 after initiation:

• ALT, AST (to catch early hepatotoxic signals from either drug)
• CBC with hematocrit (to detect rapid testosterone-driven erythrocytosis)

Every 12 weeks thereafter:

• Lipid panel
• Hepatic function panel
• CBC with hematocrit
• Total testosterone trough level

Trigger for dose modification or discontinuation:

• Hematocrit exceeding 54%: withhold testosterone per Endocrine Society guidance until hematocrit falls below 50%, then restart at a lower dose [7]
• ALT rising above 5x the upper limit of normal: discontinue resmetirom per its label and investigate cause [1]
• LDL-C increasing above pre-treatment baseline despite resmetirom: reassess testosterone dose and consider statin addition

The Endocrine Society's 2018 guideline, authored by Bhasin et al., recommends: "Measure hematocrit at baseline, at 3 to 6 months, and then annually. If hematocrit exceeds 54%, stop testosterone therapy until hematocrit decreases to a safe level" [7].

Dose Adjustment Considerations

Neither the resmetirom label nor the testosterone prescribing information mandates dose adjustment when these drugs are co-administered [1][4]. Resmetirom dosing is weight-based: 80 mg daily for patients weighing <100 kg and 100 mg daily for patients weighing 100 kg or greater [1].

Testosterone dosing follows standard endocrine targets regardless of resmetirom co-administration. The goal remains a trough testosterone level between 400 and 600 ng/dL for most men on replacement therapy [7]. No published data suggest that resmetirom alters testosterone clearance or bioavailability.

One indirect consideration exists. Resmetirom activates thyroid hormone receptor beta selectively [1]. Thyroid hormones increase sex hormone-binding globulin (SHBG) production in the liver [10]. A clinically meaningful rise in SHBG could theoretically lower free testosterone levels even if total testosterone remains stable. The MAESTRO-NASH trial did not report SHBG changes as an endpoint, and the magnitude of SHBG alteration from a selective THR-beta agonist is expected to be smaller than that from exogenous T3 or T4 [1][10]. Monitoring free testosterone alongside total testosterone captures this possibility.

Specific Testosterone Formulation Considerations

The route of testosterone administration affects the hepatic safety profile of this combination. Not all formulations carry equal risk.

Injectable testosterone cypionate or enanthate bypasses first-pass hepatic metabolism entirely. These remain the most commonly prescribed TRT formulations and carry the lowest hepatotoxic risk when paired with resmetirom [4].

Transdermal testosterone (patches, gels) also avoids significant hepatic first-pass effect. Gels produce more stable serum levels than injections, which may reduce peak-driven hematocrit spikes [7].

Oral testosterone undecanoate (Jatenzo) is absorbed via the lymphatic system, partially bypassing hepatic first-pass metabolism, but does produce measurable hepatic exposure. The Jatenzo label carries a boxed warning for blood pressure increases and notes ALT elevations in clinical trials [11]. Prescribers co-administering oral testosterone undecanoate with resmetirom should increase hepatic monitoring frequency to every 8 weeks during the first 6 months.

Subcutaneous testosterone pellets (Testopel) bypass first-pass metabolism and provide sustained release over 3 to 6 months. They require less frequent hematocrit checks during stable dosing but demand careful scheduling to align monitoring with both drug protocols.

The MASH-Hypogonadism Axis: Clinical Context

The decision to co-prescribe these agents does not happen in a vacuum. Low testosterone itself may accelerate hepatic steatosis and fibrosis progression. A prospective cohort study (N=373) published in Hepatology found that men with total testosterone below 300 ng/dL had a 2.6-fold higher odds ratio for NASH compared with eugonadal controls after adjusting for BMI and insulin resistance [12].

Treating hypogonadism may therefore support the therapeutic goals of resmetirom rather than oppose them. A 2019 RCT (N=43) of testosterone therapy in hypogonadal men with NAFLD demonstrated a reduction in intrahepatic fat measured by MRI-PDFF from 18.7% to 13.4% over 12 months [13]. This effect is mechanistically consistent: testosterone reduces visceral adiposity, improves insulin sensitivity, and decreases hepatic de novo lipogenesis [13].

The clinical calculus is nuanced. Treating the hormonal deficit may improve the liver disease that resmetirom targets. The combination is not inherently antagonistic.

When to Involve Hepatology

Most patients on resmetirom already have a gastroenterologist or hepatologist involved in their care given the F2-F3 fibrosis requirement for the drug's indication. Co-prescribing testosterone warrants a brief communication between the prescribing endocrinologist (or men's health provider) and the hepatologist.

Specific scenarios that require hepatology input before adding testosterone:

• FIB-4 score above 2.67 or liver stiffness above 12.5 kPa on FibroScan, suggesting possible cirrhosis (F4)
• Baseline ALT above 3x the upper limit of normal while on resmetirom
• History of drug-induced liver injury from any medication
• Active or planned use of oral testosterone formulations
• Concurrent use of strong CYP2C8 inhibitors (gemfibrozil, clopidogrel) that increase resmetirom exposure [1]

Patient Counseling Points

Patients prescribed both medications should understand several practical points. First, the drugs do not directly interfere with each other's absorption or metabolism. Taking them at different times of day is not necessary for pharmacokinetic reasons, though resmetirom should be taken with food as its label specifies [1].

Second, both drugs require ongoing bloodwork. Patients should expect lab draws every 12 weeks at minimum and should not skip appointments, particularly during the first 6 months of combination therapy. Third, symptoms warranting immediate medical contact include jaundice, dark urine, severe fatigue (possible hepatotoxicity), persistent headache with visual changes (possible polycythemia-related hyperviscosity), or chest pain.

Alcohol consumption compounds hepatic risk from both drugs and should be minimized. The AASLD recommends abstinence or near-abstinence for patients with MASH regardless of pharmacotherapy [8].